ArticleFrontiers in immunology2026
Comparison of the protective effect of human respiratory syncytial virus Pre-F protein combined with different adjuvants in BALB/c mice.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Human respiratory syncytial virus (HRSV) has a high disease burden in infants and elderly individuals. In this study, the adjuvants AlOH, AlOH+CpG and BFA03 were used to compare the protective effect of HRSV prefusion protein (Pre-F) in BALB/c mice. Methods: We divided BALB/c mice into three experimental groups (Pre-F+AlOH+CpG, Pre-F+AlOH, and Pre-F+BFA03) and three adjuvant control groups (AlOH+CpG, AlOH, and BFA03). After two intramuscular immunizations, we measured serum neutralizing antibody titers and quantified the numbers of IFN-γ- and IL-4-secreting lymphocytes. After viral challenge, we monitored body weight changes, determined lung viral loads (Ct values), and scored lung pathological damage. Results: The mice in the experimental groups exhibited high titres of neutralizing antibodies and increased numbers of IFN-γ- and IL-4-secreting lymphocytes. The mice began to regain weight on the third day after challenge, but the mice in the adjuvant groups continued to lose weight. The mice immunized with Pre-F+BFA03 elicited the highest neutralizing antibody titre (1716), the lowest viral load in the lung, and milder pathological damage. The mice immunized with Pre-F+AlOH had the most severe lung pathological injury (score: 2.83) and the highest viral load in the lung (Ct value: 32.2). Compared with the BFA03 adjuvant, the AlOH adjuvant induced a Th2-biased humoral immune response in mice. The Pre-F+AlOH+CpG group had the least pathological damage in the lung (score 2.16), and the ability to induce neutralizing antibodies and cellular immune responses was comparable with that of the BFA03 adjuvant. Discussion: These findings indicate that Pre-F protein combined with AlOH+CpG or BFA03 adjuvant provided similar protection in mice and both were superior to the AlOH adjuvant, providing a reference for adjuvant selection and formulation strategies in HRSV Pre-F protein vaccine development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.